Sight Sciences (NASDAQ:SGHT) Announces Quarterly Earnings Results

Sight Sciences (NASDAQ:SGHT) released its quarterly earnings results on Wednesday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01), Zacks reports. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. Sight Sciences updated its FY 2025 guidance to EPS.

Sight Sciences Stock Down 2.0 %

SGHT stock traded down $0.05 during trading on Wednesday, reaching $2.42. The stock had a trading volume of 306,586 shares, compared to its average volume of 250,791. Sight Sciences has a one year low of $2.29 and a one year high of $8.45. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The company’s 50 day moving average is $2.97 and its two-hundred day moving average is $4.46. The company has a market capitalization of $122.83 million, a price-to-earnings ratio of -2.37 and a beta of 2.52.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a report on Tuesday, January 14th. Citigroup lowered their target price on shares of Sight Sciences from $4.60 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday. UBS Group lowered their target price on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating on the stock in a report on Monday, January 27th. Lake Street Capital lowered their target price on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, January 15th. Finally, Morgan Stanley lowered their target price on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, November 11th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.42.

Insider Activity

In related news, CEO Paul Badawi sold 12,236 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.60, for a total transaction of $44,049.60. Following the sale, the chief executive officer now directly owns 5,713,197 shares in the company, valued at approximately $20,567,509.20. This represents a 0.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold 63,014 shares of company stock valued at $197,295 in the last three months. Company insiders own 28.90% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.